Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

BACKGROUND: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell death 1 (PD-1) antibody pembrolizumab. We report res...

Descripción completa

Detalles Bibliográficos
Autores principales: Curti, Brendan D, Richards, Jon, Hyngstrom, John R, Daniels, Gregory A, Faries, Mark, Feun, Lynn, Margolin, Kim A, Hallmeyer, Sigrun, Grose, Mark, Zhang, Yiwei, Li, Anlong, Andtbacka, Robert H I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791411/
https://www.ncbi.nlm.nih.gov/pubmed/36564126
http://dx.doi.org/10.1136/jitc-2022-005224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791411/
https://www.ncbi.nlm.nih.gov/pubmed/36564126
http://dx.doi.org/10.1136/jitc-2022-005224

Ejemplares similares